LON:HVO

hVIVO Final Earnings Results & Report

hVIVO logo
GBX 4.62 -0.13 (-2.74%)
As of 12:33 PM Eastern

hVIVO reported Final earnings on April 15, 2026. The company reported EPS of -GBX 0.87, while revenue was £46.77 million.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

hVIVO EPS Results

Actual EPS
-GBX 0.87
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

hVIVO Revenue Results

Actual Revenue
£46.77 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

hVIVO Final Earnings FAQ

hVIVO (LON:HVO) reported earnings of -GBX 0.87 per share for Final. The report was announced on Wednesday, April 15, 2026.

hVIVO reported revenue of £46.77 million for Final.

hVIVO Earnings Headlines

hVIVO names new finance chief to support growth strategy
Appointment of Chief Financial Officer
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
hVIVO appoints Caroline Shaw to board as Sullivan steps down
See More hVIVO Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like hVIVO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on hVIVO and other key companies, straight to your email.

About hVIVO

hVIVO (LON:HVO) (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

View hVIVO Profile